



## ***Tracells Ltd.***

### **Revolutionizing the diagnosis of Inflammation Bowel Diseases**

#### **WHO WE ARE:**

Tracells Ltd. pioneers non-invasive stool tests, utilizing a platform technology that combines patient transcriptome analysis and AI-driven classifiers for advanced and precise diagnostics of GI diseases like Inflammatory Bowel Disease and Colorectal Cancer.

#### **THE PROBLEM:**

Inflammatory Bowel Diseases (IBD) affect 0.5% of the global population, diagnosed only by invasive diagnostic methods. Current non-invasive blood and fecal tests are not specific to IBD, cannot assess inflammation location and cannot assess endoscopic remission. In ileal CD, fecal calprotectin has non-negligible false positive and false negative results.

#### **THE SOLUTION:**

Tracells' stool test utilizes RNA profiles from patients' intestinal and immune cells, which are shed into the stool, for accurate IBD diagnosis<sup>1</sup>. AI-driven analysis offers insights into inflammation severity, location, and disease type classification.

#### **THE BENEFITS:**

- **Platform technology:** Noninvasive test for capturing colonoscopy-equivalent biometric data.
- **Convenience:** Home-based stool test, decreasing reliance on invasive procedures.
- **Precision:** ~1000-gene analysis for highly accurate diagnosis.
- **Frequent Monitoring:** Non-invasive and budget-friendly, allowing for regular tracking in proactive disease management.
- **Intellectual Property:** Utilizes licensed patented technology that increases signal over noise.
- **Financial Backing:** Secured \$1M from Israel Innovation Authority (IIA) & Galilee-Ofek Incubator.

<sup>1</sup> Dan et al. CMGH 2023